NASDAQ · SLNO
Soleno Therapeutics, Inc.
Healthcare · Biotechnology
$53.010.00% ($0.00)at close
As of 4:00 PM ET
Market cap
$2.76B
P/E
29.29
EPS (TTM)
$1.81
Next earnings
Aug 5, 2026
Valuation
Revenue & margin DCF
Verdict: expensive. Price above all scenarios.
The price needs 12.4% revenue growth a year for 10 years. Our scenarios assume 2.3–4.4%.
Value per share
Base case
$28.71
Price used $53.01 is 1.8× this
USD · TTM ending Mar 31, 2026 · Price May 15, 8:00 PM UTC
Fewer than two comparable annual revenue periods are available, so growth is taken from the latest quarterly year-over-year figure without the annual cross-check.
Revenue each value needs
Revenue today $285M. The price needs $914M by 2036. Base case: $390M. Bear to Bull: $358M to $440M.
Revenue today $285M. The price needs $914M by 2036. Base case: $390M. Bear to Bull: $358M to $440M.
Revenue in 2036
today $285M
+$523Mmore than the Base case · 2.3×
Value per share · Base case
$28.71
Price $53.01
1.8× this
- 10-yr revenue CAGR
- 3.2%
- Ending operating margin
- 30.0%
- Discount rate
- 8.1%
Fewer than two comparable annual revenue periods are available, so growth is taken from the latest quarterly year-over-year figure without the annual cross-check.
USD · TTM ending Mar 31, 2026 · Price May 15, 8:00 PM UTC
What each scenario assumes. Click a column to start from it.
Price vs Fundamentals
Why The Stock Is Moving
Note: The latest financial period used here ended about 6 months ago, so a newer report is probably out. Metrics shown may not reflect it.
What changed
The stock fell 29.86% over the last year. Free cash flow grew 217.95% over the trailing twelve months.
What the market seems to be pricing
Visible fundamentals weakened far less than the stock price. The market appears to be discounting durability, risk, or trust rather than just the latest reported numbers.
What would invalidate this read
This read changes if operating margin (currently 30.8%) continues to decline, or if revenue growth turns negative. The bull case requires the business to hold its current trajectory.
Return analysis
Company profile
Soleno Therapeutics, Inc. (SLNO) operates as a clinical-stage biopharmaceutical company, specializing in the creation and market introduction of groundbreaking treatments for uncommon illnesses.
Market multiples
Stock splits
Every 15 shares became 1
Every 5 shares became 1
Profitability & growth
Analyst consensus
8
Buy
5
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Aug 5, 2026
Q2 FY26 · EPS est $0.91 · Revenue est $111.76M
View
Institutional Sentiment
Soleno Therapeutics, Inc. · SLNO
From Form 13F filings (managers with $100M+). Filings land up to 45 days after quarter end — read this as positioning context, not live fund flow.